Bayer opened a Pandora’s box when it acquired Monsanto Co. in 2018. Since acquiring the maker of Roundup weed killer, the multinational pharmaceutical giant has faced lawsuits from nearly 49,000 Roundup users who claim the product causes non-Hodgkin’s lymphoma (NHL).
Bayer CEO Werner Baumann's $63 billion gamble on purchasing Monsanto continues to spiral downward. Not only is Bayer facing more than 43,000 glyphosate claims from Roundup users afflicted with cancer, but now, a small army of farmers are lining up to sue the company over dicamba, another Monsanto herbicide that has been destroying food crops.
Three juries have determined that glyphosate, the active ingredient in the herbicide Roundup, is a carcinogen. These verdicts are in agreement with the International Agency for Research on Cancer, which concluded that glyphosate is likely to cause cancer, and other scientific studies that have linked glyphosate to the disease. However, recently published research focusing on Roundup's “inert” ingredients suggests that there may be more to it than glyphosate.
Six Roundup cancer cases are scheduled to go to trial right after the New Year, even as Bayer is attempting to negotiate a global settlement in Berlin. Among those plaintiffs are two children who suffer from non-Hodgkin's lymphoma (NHL), allegedly due to exposure to glyphosate, the active ingredient in the herbicide.
Prominent mediation attorney Kenneth Feinberg – best known as architect of the 9/11 Victims Compensation Fund – recently told the German news magazine WirtschaftsWoche (“Economic Week”) that mediation between Bayer AG and U.S. glyphosate plaintiffs is progressing – but don't look for a settlement or resolution anytime soon.
A number of glyphosate cancer cases that were scheduled to go to trial in the next several weeks have been postponed as Bayer AG attempts to reach a settlement with U.S. plaintiffs, Reuters reported this week. Assisting in the process is prominent mediation attorney Kenneth Feinberg, who is best known as the architect of the 911 Victims Compensation Fund.
In the latest blow to German-based conglomerate Bayer, the government of Germany itself has now announced that it will begin phasing out allowed uses of glyphosate, the active ingredient in the controversial herbicide Roundup.
Bayer AG got more bad news this week as the Austrian parliament voted to ban glyphosate, the active ingredient in the company's legacy flagship product, Roundup. One member of the parliament told the media, “We want to be a role model for other countries in the EU and the world.” Other European countries have passed partial bans and severe restrictions on the sale and use of glyphosate, but Austria is the first EU member to ban the herbicide outright.
Is Bayer having buyer's regret over its recent acquisition of Monsanto? It should be. For the third time in less than a year, a jury has awarded a hefty amount to plaintiffs who claim they developed non-Hodgkin's lymphoma (NHL) from using the glyphosate-based herbicide, Roundup.
The plaintiffs in the most recent case were a married couple from the San Francisco area, both of whom are in their 70s and were diagnosed with NHL. They reported having used Roundup for 35 years and were diagnosed within four years of each other.
For the second time in less than a year, a federal jury has awarded a multi-million judgment to a plaintiff who claimed his lymphoma was caused by exposure to glyphosate, the active ingredient in the herbicide RoundupTM.